¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"Ž"¿¡ ´ëÇÑ Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
1
ÄÚµå
¿µ¹®
ÇѱÛ
D76.1
Haemophagocytic lymphohistiocytosis
Ç÷±¸Å½½Ä¼º ¸²ÇÁÁ¶Á÷±¸Áõ
D76.2
Haemophagocytic syndrome, infection-associated
°¨¿°°ú °ü·ÃµÈ Ç÷±¸Å½½Ä ÁõÈıº
T36.1
Cefalosporins and other ¥â-lactam antibiotics
¼¼ÆÈ·Î½ºÆ÷¸° ¹× ±âŸ º£Å¸-¶ôްè Ç×»ýÁ¦
Y40.1
Cefalosporins and other ¥â-lactam antibiotics
¼¼ÆÈ·Î½ºÆ÷¸° ¹× ±âŸ º£Å¸¶ôŽ Ç×»ýÁ¦
Z00.6
Examination for normal comparison and control in clinical research programme
ÀÓ»ó Ž±¸ °èȹ¿¡¼ Á¤»ó ºñ±³ ¹× ÅëÁ¦¿¡ ´ëÇÑ °Ë»ç
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
ÄÚµå
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½